Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

By T. Ernst, A. Chase, J. Score, Claire E Hidalgo-Curtis, C. Bryant, A. Jones, K. Waghorn, K. Zoi, F. Ross, A. Reiter and 8 more. Nature Genetics, 2010

1,197 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/ee763dbc1c4533bd2539b56249dc62fc79426338

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. S. Baylin
2. Peter A. Jones
3. Michael R. Stratton
4. Chuan He
5. Qing Dai
6. Chun-Xiao Song
7. M. Dawson
8. Andrei Krivtsov

In Hematology

1. R. Majeti
2. M. R. Corces-Zimmerman
3. Irving L. Weissman
4. Peter A. Jones
5. Michael R. Stratton
6. M. Dawson
7. Andrei Krivtsov
8. Tony Kouzarides

In Molecular Biology

1. Peter A. Jones
2. S. Baylin
3. J. Simon
4. Chuan He
5. Robert E. Kingston
6. Tony Kouzarides
7. Peter J. Campbell
8. M. Dawson

Citations in the corpus

• Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. (2014, neutral): “Neutrophils (10(9)/L) average (range) 9 (2-36) 6 (3-16) 8 (3-21)”
• Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put (2013, background): “These critical findings are accompanied by the paradox that PcG mutations found in B cell lymphomas cause gain of function, whereas mutations in T cell and myeloid leukemia subtypes are loss-of-function (Ernst et al., 2010; Ntziachristos et al., 2012).”
• MLL-rearranged Leukemia is Dependent on Aberrant H3K79 Methylation by DOT1L (2011, positive): “Genes encoding histone methyltransferase EZH2 and DNA methyltransferase DNMT3a are frequently mutated in hematopoietic malignancies (Ernst et al., 2010; Ley et al., 2010; Morin et al., 2010; Nikoloski et al., 2010), and recent trials have demonstrated clinical efficacy of epigenetic-directed…”
• Cancer epigenetics: from mechanism to therapy. (2012, background): “In contrast, loss-of-function mutations in EZH2 gene, conferring a poor prognosis, have been described in the myeloid malignancies (Ernst et al., 2010; Nikoloski et al., 2010) and T-ALL (Ntziachristos et al., 2012; Zhang et al., 2012), suggesting a tumor-suppressive role for EZH2 in these cell…”
• Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation (2011, positive): “These include somatic mutations in chromatin-modifying enzymes (Ernst et al., 2010; Nikoloski et al., 2010) and in DNAmethyltransferases (Ley et al., 2010; Yamashita et al., 2010).”